Evidence Grade A — Regulatory approved. 375 published studies. 167 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Degarelix (sold as Firmagon) is a monthly injection for advanced prostate cancer that suppresses testosterone — the hormone that fuels prostate cancer growth. Unlike older hormone treatments that cause a temporary surge in testosterone before shutting it down, degarelix blocks hormone signals immediately. This matters most for patients with symptoms like bone pain, where a hormone surge could make things worse.
Degarelix is also known by these brand and alternate names:
375 published studies: 245 human, 28 animal, 17 in-vitro, 74 reviews
Degarelix is marketed as Firmagon (approved December 2008) for advanced prostate cancer. It is administered as a monthly subcutaneous injection, with a loading dose of 240 mg followed by 80 mg monthly. Injection-site reactions are common (pain in 35%, redness in 32%).
The key clinical advantage of degarelix over traditional GnRH agonists is the absence of testosterone flare, making it particularly suitable for patients with symptomatic metastatic disease where a hormone surge could worsen bone pain or urinary obstruction. It achieves castrate testosterone levels within three days. However, monthly injections with notable injection-site discomfort have limited its uptake compared to longer-acting GnRH agonist depots, and the oral GnRH antagonist relugolix has emerged as a more convenient alternative with potential cardiovascular advantages.
Unlike GnRH agonists (such as leuprolide and goserelin) which overstimulate and then exhaust the hormone system, degarelix directly blocks the GnRH receptor in the pituitary gland, preventing hormone signals from getting through at all. This means testosterone levels drop immediately — within days rather than weeks — and critically, there is no initial hormone surge or 'flare' effect. This distinction matters clinically because the flare can temporarily worsen prostate cancer symptoms and requires additional medication to manage.
Degarelix achieves castrate testosterone levels within three days, avoiding the one-to-two-week hormone surge ("flare") seen with older GnRH agonist treatments. The CS21 trial showed faster initial disease marker suppression compared to the agonist leuprolide. For patients at risk of flare-related complications — such as spinal cord compression or urinary obstruction from tumour swelling — this immediate suppression is a meaningful clinical advantage. However, degarelix requires monthly injections that frequently cause injection-site pain (35%) and redness (32%), which has limited its uptake compared to longer-acting alternatives. The oral GnRH antagonist relugolix (Orgovyx) has further reduced degarelix's niche by offering the same flare-free suppression in a daily tablet with potential cardiovascular advantages, as demonstrated in the HERO trial.
PeptideTrace tracks 167 registered clinical trials for Degarelix sourced from ClinicalTrials.gov.
Open-Label, Randomised Parallel-Group Study
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer
FDA ORIG 1
Health Canada Market Authorisation
FDA SUPPL 2
FDA SUPPL 3
FDA SUPPL 4
FDA SUPPL 5
FDA SUPPL 6
FDA SUPPL 8
FDA SUPPL 9
FDA SUPPL 10
FDA SUPPL 11
FDA SUPPL 12
FDA SUPPL 13
FDA SUPPL 16
EMA Marketing Authorisation
Degarelix is a synthetic linear decapeptide (10 amino acids) GnRH antagonist containing 7 unnatural amino acids. Unlike GnRH agonists, it acts as a competitive receptor antagonist, blocking GnRH binding and immediately suppressing gonadotropin release without an initial hormonal flare.
Degarelix binds competitively to GnRH receptors in the anterior pituitary, directly blocking endogenous GnRH from stimulating LH and FSH release. This produces immediate and sustained testosterone suppression without the initial surge seen with GnRH agonists. Castrate testosterone levels are achieved by day 3 in 96.1% of patients (versus 0% with leuprolide at day 3). At the injection site, degarelix forms a gel-like depot from which it is slowly released.
Degarelix is marketed as Firmagon (approved December 24, 2008) for advanced prostate cancer. Administered as monthly subcutaneous injection (loading dose 240 mg, then 80 mg monthly). Prominent injection-site reactions are common (pain 35%, erythema 32%). In the pivotal trial (N=610), degarelix achieved castrate testosterone in 98.3% by day 28, noninferior to leuprolide.
Carbetocin has not been approved by the FDA. It is registered in over 80 countries for prevention of uterine atony and excessive bleeding after caesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019. The CHAMPION trial (WHO, 2018; over 29,000 women) compared a heat-stable carbetocin formulation to oxytocin for preventing postpartum haemorrhage after vaginal delivery, and found it to be non-inferior. The heat-stable formulation addresses a significant limitation of oxytocin, which degrades in warm climates without refrigeration — a major concern in low-resource settings where postpartum haemorrhage causes the most deaths. Its regulatory status varies by jurisdiction.
Kisspeptin-54 has no marketing authorisation. Phase II trials conducted primarily at Imperial College London have investigated its use as an IVF oocyte maturation trigger. One trial (60 patients) reported 95% oocyte maturation with zero cases of ovarian hyperstimulation syndrome. Kisspeptin-54 has a more advanced clinical evidence base than kisspeptin-10, with multiple Phase II studies in reproductive medicine. Its potential advantage over conventional IVF triggers relates to a lower risk of the serious complication of ovarian hyperstimulation. Clinical development is ongoing in academic settings. No Phase III trials have been completed.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Comparisons
Regulatory Status
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
